Arvinas, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
5
Bearish
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
ARVN
Clean balance sheet with low leverage (0.0× debt-to-equity).
⚠ currently unprofitable (-31% margin).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
HOLD
Target $14.88 (+41.5%)
16 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
ARVN
PFE
—
Trailing P/E
19.4×
-3.0×
Forward P/E
9.4×
-30.8%
Profit Margin
12.4%
100.0%
Gross Margin
75.8%
-16.2%
ROE
8.9%
-84.0%
Revenue Growth
-1.2%
—
Earnings Growth
—
1.98
Beta
0.39
—
Price / Book
—
$672M
Market Cap
$149.8B
$6 – $15
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →